arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

AMARIN CORP PLCUK

AMRN
$11.54 ▼ -0.77 (-6.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

AMARIN CORP PLCUK faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8B
Dividend Yield —
Revenue Growth -20.4% ↗
Op. Margin -6.0% ↗
ROIC -0.4% ↗
FCF / Share $0.02 ↗
Trailing P/E —
Price / Book 11.0x
FCF Yield 0.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$39.55M
↓ -20.4% —
Net Income Profit after all expenses
$-10.51M
↑ +33.0% —
Operating Margin Operating profit as % of sales
-6.0%
↑ +79.0% 9th
FCF / Share Free cash flow per share
$0.02
↑ +39.2% —
Long-Term Debt Long-term obligations
$9.39M
↓ -57.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
19
Returns
35
Financial Health
1
Cash Quality ↑
17

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters